An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

Most gene mutations that lead to lung cancer happen because of things you’ve been exposed to. Tobacco is the most common cause of genetic changes to lung cells, but it isn’t the only one.

The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ... the most common type of lung cancer.

Sabari, MD, which focused on the first-line approval of amivantamab (Ami; Rybrevant; Johnson & Johnson) plus lazertinib ...

Orserdu showed similar or slightly better real-world outcomes compared to EMERALD trial PFS in HR-positive, HER2-negative ...